Literature DB >> 19698778

Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors.

Cornelia Kiank1, Yvette Taché, Muriel Larauche.   

Abstract

The interaction between gut inflammatory processes and stress is gaining increasing recognition. Corticotropin-releasing factor (CRF)-receptor activation in the brain is well established as a key signaling pathway initiating the various components of the stress response including in the viscera. In addition, a local CRF signaling system has been recently established in the gut. This review summarize the present knowledge on mechanisms through which both brain and gut CRF receptors modulate intestinal inflammatory processes and its relevance towards increased inflammatory bowel disease (IBD) activity and post-infectious irritable bowel syndrome (IBS) susceptibility induced by stress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19698778      PMCID: PMC2962412          DOI: 10.1016/j.bbi.2009.08.006

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  89 in total

Review 1.  Stress hormones and immune function.

Authors:  Jeanette I Webster Marketon; Ronald Glaser
Journal:  Cell Immunol       Date:  2008-02-14       Impact factor: 4.868

Review 2.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

3.  Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia.

Authors:  Mauricio Rosas-Ballina; Mahendar Ochani; William R Parrish; Kanta Ochani; Yael T Harris; Jared M Huston; Sangeeta Chavan; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

Review 4.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

5.  Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension.

Authors:  K Saito-Nakaya; R Hasegawa; Y Nagura; H Ito; S Fukudo
Journal:  Neurogastroenterol Motil       Date:  2008-08-28       Impact factor: 3.598

Review 6.  Is irritable bowel syndrome an inflammatory disorder?

Authors:  Roberto De Giorgio; Giovanni Barbara
Journal:  Curr Gastroenterol Rep       Date:  2008-08

Review 7.  Corticotropin-releasing factor receptor-1: a therapeutic target for cardiac autonomic disturbances.

Authors:  Susan K Wood; James H Woods
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

8.  Corticotropin-releasing hormone deficiency is associated with reduced local inflammation in a mouse model of experimental colitis.

Authors:  Jérôme Gay; Efi Kokkotou; Michael O'Brien; Charalabos Pothoulakis; Katia P Karalis
Journal:  Endocrinology       Date:  2008-04-10       Impact factor: 4.736

9.  Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro.

Authors:  C Wallon; P-C Yang; A V Keita; A-C Ericson; D M McKay; P M Sherman; M H Perdue; J D Söderholm
Journal:  Gut       Date:  2007-05-24       Impact factor: 23.059

Review 10.  The neuroendocrinology of stress: a never ending story.

Authors:  S L Lightman
Journal:  J Neuroendocrinol       Date:  2008-06       Impact factor: 3.627

View more
  41 in total

Review 1.  The Costs of Living Together: Immune Responses to the Microbiota and Chronic Gut Inflammation.

Authors:  Lucas J Kirschman; Kathryn C Milligan-Myhre
Journal:  Appl Environ Microbiol       Date:  2019-05-02       Impact factor: 4.792

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

3.  Epinephrine-primed murine bone marrow-derived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-γ by CD4+ T cells.

Authors:  Byung-Jin Kim; Harlan P Jones
Journal:  Brain Behav Immun       Date:  2010-05-31       Impact factor: 7.217

Review 4.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

5.  Corticotropin-releasing factor augments LPS-induced immune/inflammatory responses in JAWSII cells.

Authors:  Yue Hu; Meng Li; Bin Lu; Xi Wang; Chaoying Chen; Meng Zhang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 6.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 7.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

8.  From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome.

Authors:  Oscar Rodríguez-Fandiño; Joselín Hernández-Ruiz; Max Schmulson
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

9.  Corticotropin releasing factor in the rat colon: expression, localization and upregulation by endotoxin.

Authors:  P-Q Yuan; S V Wu; L Wang; Y Taché
Journal:  Peptides       Date:  2009-11-26       Impact factor: 3.750

10.  The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.

Authors:  Alicia Arranz; Maria Venihaki; Berber Mol; Ariadne Androulidaki; Erini Dermitzaki; Olga Rassouli; Jorge Ripoll; Efstathios N Stathopoulos; Rosa P Gomariz; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2010-09-27       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.